Physician profile
Sandra Rivera
NPI 1093260416
$1,636.57
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,042 · 2022: $595.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $897.12 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $164.11 | 2021-2022 | |
| Biodelivery Sciences International, INC. | $145.33 | 2021 | |
| Abbott Laboratories | $112.43 | 2021 | |
| Gilead Sciences, INC. | $78.51 | 2022 | |
| Pacira Therapeutics, INC. | $55.37 | 2021 | |
| Fidia Pharma USA INC. | $38.00 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $28.79 | 2021 | |
| Horizon Therapeutics Plc | $24.42 | 2022 | |
| Relievant Medsystems, INC. | $21.54 | 2021 | |
| Insulet Corporation | $18.05 | 2021 | |
| Smith+Nephew, INC. | $14.36 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.16 | 2021 | |
| Metacel Pharmaceuticals LLC | $13.31 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.07 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.